Public Release: 

Wbp2 is a novel gene implicated in deafness



The scientists have shown that hearing impairment is linked to hormonal signalling rather than to hair cell degeneration. Wbp2 is known as a transcriptional co-activator for estrogen receptor Esr1 and progesterone receptor Pgr. The loss of Wbp2 causes not only progressive high frequency hearing loss, but also results in reduced expression of Esr1, Esr2 and Pgr in the cochlea -- a part of the inner ear. Understanding the estrogen-sensitive molecular networks specific to hearing offers an unprecedented putative new target for the control of the estrogen signalling pathway in the auditory system that could prevent or reverse progressive hearing loss.

"Our study demonstrates that hearing thresholds are normal in young Wbp2 mutant mice, but are raised at high frequencies by four weeks of age," says EMBO Member Karen Steel of King's College London, the senior author of the study. "More importantly, we also demonstrate that Wbp2 is crucial for hearing in humans. We found two children affected by severe to profound deafness, each carrying two variants of the WBP2 gene."

Progressive hearing loss is a very common disease. However, very little is known about its molecular mechanisms. As a result, targets for medical therapies have been lacking. It has been known that estrogen signalling protects against noise-induced hearing loss. However, estrogen-based therapies have not been generally considered for hearing impairment due to their widespread effects. This study opens up the Wbp2 pathway as a new route to therapeutic approaches that more specifically target the inner ear.


Wbp2 is required for normal glutamatergic synapses in the cochlea and is crucial for hearing.


Annalisa Buniello, Neil J Ingham, Morag A Lewis, Andreea C Huma, Raquel Martinez-Vega, Isabel Varela-Nieto, Gema Vizcay-Barrena, Roland A Fleck, Oliver Houston, Tanaya Bardhan, Stuart L Johnson, Jacqueline K White, Huijun Yuan, Walter Marcotti, Karen P Steel

Read the paper:

doi: 10.15252/emmm.201505523

Further information on EMBO Molecular Medicine is available at

Media Contacts

Yvonne Kaul
Communications Officer

Céline Carret
Editor, EMBO Molecular Medicine
Tel: +49 6221 8891 411

About EMBO


